Pharming Group (PHAR) Projected to Post Quarterly Earnings on Thursday

Pharming Group (NASDAQ:PHAR) will likely be releasing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $0.0630 per share and revenue of $99.5160 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 7:30 AM ET.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.12). Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.The business had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million. On average, analysts expect Pharming Group to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Pharming Group Price Performance

NASDAQ PHAR opened at $12.86 on Wednesday. Pharming Group has a fifty-two week low of $9.54 and a fifty-two week high of $21.34. The stock’s 50-day moving average is $13.13 and its two-hundred day moving average is $15.33. The firm has a market cap of $910.23 million, a P/E ratio of 80.38 and a beta of -0.04. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.63 and a quick ratio of 2.06.

Analyst Ratings Changes

PHAR has been the topic of a number of analyst reports. Weiss Ratings lowered Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Canaccord Genuity Group assumed coverage on Pharming Group in a research report on Friday, April 10th. They set a “buy” rating and a $37.00 target price for the company. Finally, Wall Street Zen downgraded Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $38.33.

Hedge Funds Weigh In On Pharming Group

A number of institutional investors have recently made changes to their positions in PHAR. NewEdge Advisors LLC grew its holdings in Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after buying an additional 28,615 shares during the last quarter. Millennium Management LLC bought a new position in Pharming Group in the 4th quarter worth approximately $360,000. SmartHarvest Portfolios LLC acquired a new position in shares of Pharming Group during the fourth quarter worth approximately $224,000. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of Pharming Group during the second quarter worth approximately $32,000. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.